Welcome to our dedicated page for Natural Alternatives International news (Ticker: NAII), a resource for investors and traders seeking the latest updates and insights on Natural Alternatives International stock.
Natural Alternatives International, Inc. (NAI), headquartered in Carlsbad, California, is a prominent player in the nutritional supplements industry. Established in 1980, NAI specializes in the formulation, manufacturing, and marketing of customized nutritional supplements. The company's unique approach combines clinical research, science-based formulations, and advanced quality assurance testing methodologies to produce superior nutritional products. These are specifically designed to address various health conditions and meet the highest standards.
NAI operates through two primary segments: Private-Label Contract Manufacturing and Patent & Trademark Licensing. The majority of the company's revenue is derived from the Private-Label Contract Manufacturing segment, offering tailored manufacturing services to firms that market and distribute nutritional and healthcare products. The Patent & Trademark Licensing segment earns income through royalty agreements linked to the sale of licensed products, such as their proprietary CarnoSyn® beta-alanine.
In recent developments, NAI temporarily closed its new high-speed powder blending and packaging facility in Carlsbad due to an inventory rebalance by one of its largest customers. Despite this, the company remains optimistic about its long-term growth. For example, CarnoSyn® beta-alanine sales saw a significant increase, showing robust demand for its patented ingredients.
Financially, NAI reported net sales of $35.9 million in the fourth quarter of fiscal year 2023, marking a decrease from the prior year. This decline was primarily due to softened consumer demand and reduced orders as customers adjusted their inventory levels. However, the company saw a marked increase in CarnoSyn® beta-alanine sales, reflecting the strength of its patent and trademark licensing segment.
As of late 2023, NAI's financial health remains solid, with a working capital of $42.3 million and cash reserves of $16.7 million. The company continues to invest in relationship development and product innovation to drive future growth, confident in its ability to navigate current economic headwinds.
NAI's comprehensive partnership approach includes support services such as scientific research, clinical studies, regulatory compliance supervision, and marketing assistance. This holistic service model distinguishes NAI in the industry, making it a go-to partner for businesses looking for customized nutritional product solutions.
Natural Alternatives International, Inc. (NAII) reported a strong performance in Q4 2022, achieving $52.5 million in net sales, up 18.3% year-over-year. Net income rose to $3.1 million or $0.52 per diluted share, compared to $3.0 million and $0.47 in Q4 2021. However, overall annual sales decreased 4.2% to $171 million. The company anticipates 10%-15% net sales growth for fiscal 2023, but warns of potential operating income impacts due to inflation and rising operational costs. They also outlined ongoing challenges in their supply chain and have begun constructing a new manufacturing facility.
Natural Alternatives International (NAII) reported a 30.7% increase in net income for Q3 FY2022, totaling $2.5 million or $0.41 per diluted share. Net sales, however, fell 8.5% to $42.4 million, driven by a 10.8% drop in private-label contract manufacturing sales due to a 40% reduction in sales from its largest customer. Despite ongoing supply chain issues, NAII anticipates 18%-21% growth in net sales for Q4 FY2022. The company holds $18.6 million in cash and a working capital of $53.8 million, showcasing resilience amid challenges.
Natural Alternatives International, Inc. (NAII), a leader in custom nutritional supplement manufacturing, has appointed Aaron Starr as the new Vice President of CarnoSyn Brands. In this role, Starr will oversee operational performance, manage P&L, and implement strategic planning and marketing initiatives aimed at enhancing customer relationships. He brings extensive experience from his previous positions at NAI and holds an MBA in Financial Management. This leadership change aims to bolster sales and expand opportunities in the sports nutrition and health sectors.
Natural Alternatives International (NAII) reported a net income of $1.8 million, or $0.30 per diluted share, on net sales of $37.7 million for Q2 fiscal 2022, down from $3.6 million and $48.1 million in Q2 fiscal 2021. Private-label contract manufacturing sales fell by 25.7% to $33.7 million, mainly due to a 48% drop from their largest customer, compounded by supply chain issues. Conversely, CarnoSyn® sales rose by 46.9% to $4.1 million. For the first half of fiscal 2022, net income was $5.1 million, down from $5.9 million. Looking ahead, NAII anticipates slight growth in net sales for fiscal 2022.
Natural Alternatives International, Inc. (NAII) announces the appointment of Sherri Balzer as Business Development Manager for CarnoSyn Brands. With over 25 years in the health and wellness sector, Balzer aims to enhance growth through strategic client management and partnerships. Her experience includes senior roles at Kb Pure Essentials and Cultivate. Balzer emphasizes her commitment to improving consumer health and plans to focus on SR CarnoSyn, which offers clinically proven benefits. This addition is expected to boost revenue and market share for NAII in the health and wellness industry.
Natural Alternatives International, Inc. (NAII) announced a $3.0 million increase in its stock repurchase plan, raising the total authorized amount to $18.0 million. The company has already repurchased 1.9 million shares at an average price of less than $8 per share since the plan's inception. NAII's CEO believes the stock is undervalued and expresses confidence in the company's growth potential, particularly with a new manufacturing facility expected to be operational by Fall 2022.
Natural Alternatives International, Inc. (NAII) reported a net income of $3.3 million or $0.51 per diluted share for Q1 FY2022, a rise from $2.3 million or $0.35 per share in the previous year. Net sales declined by 3.5% to $38.3 million, influenced by a 45% drop in sales to its largest customer due to European market issues. However, CarnoSyn® sales surged by 77.1% to $4.7 million. Looking forward, NAII anticipates a 7-10% increase in FY2022 net sales despite first-half declines due to supply chain constraints.
Natural Alternatives International, Inc. (NAI) will release its first quarter 2022 financial results on November 9, 2021, after market close. The company's operations include the formulation and marketing of customized nutritional supplements and strategic partnerships. A comprehensive investor presentation will be available following the earnings release. The press release includes forward-looking statements and cautions about potential risks and uncertainties affecting future financial performance. Further details can be found on NAI's website.
Natural Alternatives International (NAII) is participating in SupplySide West on October 27-28, 2021, at booth #5472. The company specializes in customized nutritional supplement manufacturing, featuring patented products like CarnoSyn® and SR CarnoSyn® beta-alanine. NAII aims to support consumer health and wellness through innovative formulations. Additionally, NAII recently became the first to meet the new standards set by the Supplement Safety & Compliance Initiative (SSCI) and expanded its manufacturing capabilities in Carlsbad, CA.
Natural Alternatives International (NAII) reported a strong fiscal Q4 2021, posting a net income of $3.0 million, or $0.47 per diluted share, on sales of $44.4 million, a 26.5% increase from the previous year. Annual net income for FY 2021 reached $10.8 million, with sales up 50.2% to $178.5 million. Private-label contract manufacturing sales rose by 54.6%, attributed to increased demand for immune products during the pandemic. Anticipating a 5-10% sales increase for FY 2022, NAII expects initial challenges in the first half due to supply chain issues, but positive growth is anticipated in the latter half.
FAQ
What is the current stock price of Natural Alternatives International (NAII)?
What is the market cap of Natural Alternatives International (NAII)?
What does Natural Alternatives International, Inc. (NAI) specialize in?
How does NAI support its clients?
What are the primary business segments of NAI?
What recent challenges has NAI faced?
How did CarnoSyn® beta-alanine sales perform recently?
What is the financial condition of NAI?
Where is NAI headquartered?
What year was NAI founded?
What sets NAI apart from other companies in the industry?
What are NAI's future plans for growth?
